Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.52 |
| ▸ | MPL | P40238 | 1/20 | 0.45 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653771 | 0.90 | FGFR4 (0.54) | FGFR4GPR142KMOSCN9ACA2 | |
| SCHEMBL12654380 | 0.89 | FGFR4 (0.52) | FGFR4GPR142KMOCA2CA9 | |
| SCHEMBL12654624 | 0.89 | FGFR4 (0.44) | FGFR4GPR142FYNKMOSCN9A | |
| SCHEMBL12958969 | 0.88 | FGFR4 (0.49) | FGFR4GPR142KMOCA9FAAH | |
| SCHEMBL12653800 | 0.88 | GPR142 (0.53) | FGFR4GPR142KMOCA2CA9 | |
| SCHEMBL12654416 | 0.87 | FGFR4 (0.49) | FGFR4MPLGPR142FYNSCN9A | |
| SCHEMBL12959025 | 0.86 | FGFR4 (0.59) | FGFR4GPR142FYNKMOSCN9A | |
| SCHEMBL12654642 | 0.86 | MPL (0.43) | FGFR4MPLGPR142FYNKMO | |
| SCHEMBL12654617 | 0.85 | GPR142 (0.53) | FGFR4GPR142FAAH | |
| SCHEMBL17655342 | 0.85 | MPL (0.47) | FGFR4MPLFYNKMOCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011059839-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FGFR4 1940/4885MPL 1128/4885GPR142 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.